Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chong Kun Dang Pharmaceutical
A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan (CamtoBell inj.) or Topotecan in Patients with Recurrent or Refractory Ovarian Cancer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age
Histological or cytological diagnosis of AOC
Stable disease (SD) or progression at time of study entry Recurrent or progressive AOC ≥ 90 days of duration of response for first-line therapy
Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent diseases
Prior anticancer therapy within 4 weeks before enroll
Active pregnancy test and Pregnant or nursing women
Participation in any investigational drug study within 28 days prior to study entry